

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/919,162	07/31/2001	Jean-Christophe Renauld	LUD 5684.2 CIP (10106926)	3161	
Fulbright & Jav	7590 02/15/2007 vorski LLP		EXAMINER		
666 Fifth Aven	ue		JIANG, DONG		
New York, NY 10103			ART UNIT	PAPER NUMBER	
			1646		
			MAIL DATE	DELIVERY MODE	
			02/15/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
09/919,165			EXAMINER	
			ART UNIT	PAPER
				20070208
			DATE MAILED	· :

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, SEQ ID NO:5 (775 nucleotides) in the paper copy of the "Sequence Listing" is not the same as the SEQ ID NO:5 (776 nucleotides) in the computer readable form. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825).

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Dong Jiang whose telephone number is 571-272-0872. The examiner can normally be reached on Monday- Friday, 10:00 to 6:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on 571-272-0835.

PATENT EXAMINES

		Application No.		Applicant(s)						
		091919	162							
	Notice to Comply	Examiner		Art Unit						
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS										
	CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE									
	DISCLOSURES									
	Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).									
	The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):									
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).									
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).									
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).									
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."									
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).									
☐ 7. Other:										
	Applicant Must Provide: ☑ An initial or substitute computer readal	ole form (CRF) copy o	of the "Sequ	ence Listing".						
		e "Sequence Listing",	as well as a	an amendment di	recting its entry					
,	☑ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).									
	For questions regarding compliance to these requirements, please contact:									
	For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212									
	Patentin Software Program Support									
	Technical Assistance	70								
	To Purchase Patentin Software	 70	3-306-26	00						
	PLEASE RETURN A COPY OF TH	IIS NOTICE WITH	YOUR R	EPLY						